Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p19
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 19/191)
Character Range: 9655871–9669150

have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids;
                                                                                                                                                                                                                               Patient must be aged 12 years or over.
C4747               P4747          CN4747           Escitalopram                                                                                                                                                               Moderate to severe generalised anxiety disorder (GAD)
                                                                                                                                                                                                                               The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
                                                                                                                                                                                                                               Patient must not have responded to non-pharmacological therapy; AND
                                                                                                                                                                                                                               Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared.
C4755               P4755          CN4755           Citalopram                                                                                                                                                                 Major depressive disorders

                                                    Escitalopram

                                                    Fluoxetine

                                                    Fluvoxamine

                                                    Paroxetine

                                                    Sertraline

C4756               P4756          CN4756           Escitalopram                                                                                                                                                               Moderate to severe generalised anxiety disorder (GAD)
                                                                                                                                                                                                                               The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
                                                                                                                                                                                                                               Patient must not have responded to non-pharmacological therapy; AND
                                                                                                                                                                                                                               Patient must have been assessed by a psychiatrist.
C4757               P4757          CN4757           Escitalopram                                                                                                                                                               Moderate to severe social anxiety disorder (social phobia, SAD)
                                                                                                                                                                                                                               The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND
                                                                                                                                                                                                                               Patient must not have responded to non-pharmacological therapy; AND
                                                                                                                                                                                                                               Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared.
C4785               P4785          CN4785           Cetuximab                                                                                                                                                                  Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 4785
                                                                                                                                                                                                                               Initial treatment
                                                                                                                                                                                                                               The treatment must be in combination with radiotherapy; AND
                                                                                                                                                                                                                               Patient must be unable to tolerate cisplatin.
C4788               P4788          CN4788           Cetuximab                                                                                                                                                                  Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 4788
                                                                                                                                                                                                                               Continuing treatment
                                                                                                                                                                                                                               The treatment must be in combination with radiotherapy; AND
                                                                                                                                                                                                                               Patient must be unable to tolerate cisplatin.  or
                                                                                                                                                                                                                               Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.
C4793               P4793          CN4793           Arsenic                                                                                                                                                                    Acute promyelocytic leukaemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 4793
                                                                                                                                                                                                                               Induction and consolidation treatment
                                                                                                                                                                                                                               The condition must be characterised by the presence of the t(15:
                                                                                                                                                                                                                                17) translocation or PML/RAR-alpha fusion gene transcript; AND
                                                                                                                                                                                                                               The condition must be relapsed; AND
                                                                                                                                                                                                                               Patient must be arsenic naive at induction.
C4794               P4794          CN4794           Cetuximab                                                                                                                                                                  Stage III, IVa or IVb squamous cell cancer of the larynx, oropharynx or hypopharynx                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Compliance with Authority Required procedures - Streamlined Authority Code 4794
                                                                                                                                                                                                                               Initial treatment
                                                                                                                                                                                                                               The treatment must be for the week prior to radiotherapy; AND
                                                                                                                                                                                                                               Patient must have a contraindication to cisplatin according to the TGA-approved Product Information.
C4796               P4796          CN4796           Exemestane                                                                                                                                                                 Metastatic (Stage IV) breast cancer
                                                                                                                                                                                                                               The condition must be hormone receptor positive; AND
                                                                                                                                                                                                                               The condition must